Pharmadrug Inc.: PharmaDrug Enters into Employment Agreement with Dr. Paul Van Slyke and Grants Him Options and Promotes Him to Chief Scientific Officer for All of Pharmadrug
PharmaDrug" or the "
Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into an employment agreement with Dr. Paul Van Slyke and promoted him to Chief Scientific Officer (CSO) for all of PharmaDrug Inc.
As part of the employment agreement, and pursuant to the terms and conditions of the Company's stock option plan, the PharmaDrug Board of Directors has approved the grant of 2,000,000 stock options to Paul Van Slyke. The options expire five years from the date of grant and are exercisable at a price of $0.09 per common share. 500,000 of the options vest immediately and 1,500,000 of the options vest in one half increments after 6 months and 12 months.